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The phosphorylation sites on the human, 85-kDa cyto-
solic phospholipase A2 (cPLA2) were identified using
recombinant cPLA2 expressed in Spodoptera frugiperda
(Sf9) cells. Analysis by high performance liquid chroma-
tography of tryptic digests of
32P-labeled recombinant
cPLA2 showed four major peaks of radiolabeled phos-
phopeptides. The phosphorylated residues were identi-
fied as Ser-437, Ser-454, Ser-505, and Ser-727 using mass
spectrometry and automated Edman sequencing. Sf9
cells infected with recombinant virus expressing cPLA2
exhibited a time-dependent release of arachidonic acid
in response to the calcium ionophore A23187 or the pro-
tein phosphatase inhibitor okadaic acid, which was not
observed in Sf9 cells infected with wild-type virus. Stim-
ulation of Sf9 cells with A23187 and okadaic acid also
increased the level of phosphorylation of cPLA2. Oka-
daic acid, but not A23187, induced a gel shift of cPLA2
and increased the level of phosphorylation of Ser-727 by
4.5-fold, whereas the level of phosphorylation of the
other sites increased by 60% or less in response to both
agonists. To determine whether the same sites on cPLA2
were phosphorylated in mammalian cells, human mono-
cytes were studied. Okadaic acid stimulation of mono-
cytes induced a gel shift of cPLA2, increased the release
of arachidonic acid, and increased the level of phospho-
rylation of cPLA2 on serine residues. Comparison of
two-dimensional peptide maps of tryptic digests of
32P-
labeled recombinant cPLA2 and human monocyte cPLA2
demonstrated that the same peptides on cPLA2 were
phosphorylated in mammalian cells as in insect cells.
These results show that the Sf9-baculovirus expression
system is useful for investigation of the phosphorylation
sites on cPLA2. The results also suggest that phospho-
rylation of the cPLA2 by protein kinases other than mi-
togen-activated protein kinase may be important for the
regulation of arachidonic acid release.
Arachidonic acid is the precursor for a variety of proinflam-
matory lipid mediators including the leukotrienes and prostag-
landins. The production of these potent agents is largely con-
trolled by the availability of free arachidonic acid. The release
of arachidonic acid from membrane phospholipid is a regulated
process that is catalyzed by phospholipase A2 and occurs in
many cell types in response to a variety of physiological and
pharmacological agonists. Current evidence implicates the 85-
kDa, cytosolic PLA2 (cPLA2)
1 as an important enzyme in me-
diating agonist-induced arachidonic acid release and eico-
sanoid production (1, 2). cPLA2, which shows specificity for
arachidonic acid-containing substrates (3–5), is posttransla-
tionally regulated both by phosphorylation and by the level of
intracellular calcium. Calcium is not required for catalytic ac-
tivity of cPLA2 but is required for binding of the cPLA2 to
phospholipid vesicles (6–8). Calcium-dependent membrane
binding of cPLA2 occurs at calcium concentrations of 300 nM or
greater and is mediated by a calcium-dependent lipid binding
domain present at the amino terminus of cPLA2 (6, 9, 10).
Stimulation of mast cells by calcium ionophore or by IgE/
antigen has recently been shown to induce translocation of the
cPLA2 from the cytosol to the nuclear membrane (11).
Treatment of a variety of cell types with diverse physiological
agonists such as growth factors, thrombin, colony-stimulating
factor-1, interleukin-1, lipopolysaccharide (LPS), bacteria, va-
sopressin, and zymosan induce phosphorylation of cPLA2 re-
sulting in an increase in its activity (1, 12–17). In stimulated
macrophages, platelets, fibroblasts, and Chinese hamster
ovary cells, phosphorylation of cPLA2 occurs exclusively on
serine residues (1, 13, 18). cPLA2 is a substrate for protein
kinase C, cyclic AMP dependent kinase (protein kinase A), and
mitogen-activated protein (MAP) kinase in vitro, but only phos-
phorylation by MAP kinase induces a consistent increase in
cPLA2 activity and decreases its electrophoretic mobility (gel
shift) (19–21). cPLA2 has one consensus site for MAP kinase at
Ser-505 (21). Evidence for a role for MAP kinase in cPLA2
phosphorylation and activation has been provided in transfec-
tion studies showing that agonist-stimulated arachidonic acid
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6987release is diminished in Chinese hamster ovary cells overex-
pressing cPLA2 that has been mutated at Ser-505 compared
with arachidonic acid release that is seen in cells overexpress-
ing the wild-type enzyme (21). Although a role for MAP kinase
phosphorylation of cPLA2 is implicated, analysis of two-dimen-
sional phosphopeptide maps of
32P-labeled cPLA2 from stimu-
lated macrophages suggests that this enzyme is phosphoryl-
ated on multiple sites and that several of these sites show
increased phosphorylation after cell stimulation (13). Recent
studies have also provided evidence for MAP kinase-indepen-
dent pathways leading to cPLA2 phosphorylation and activa-
tion (18, 22, 23).
Identification of the phosphorylation sites on cPLA2 is im-
portant for understanding its mechanisms of regulation. To
identify the phosphorylation sites, we have taken advantage of
the baculovirus expression system in which we have previously
demonstrated that cPLA2 is expressed as a phosphoprotein and
from which large amounts of cPLA2 can be obtained (24). It has
been observed that the sites that are phosphorylated on pro-
teins expressed in baculovirus-infected insect cells and mam-
malian cells are often the same (25, 26). A recent report has
demonstrated that cPLA2 is phosphorylated on Ser-505 when
expressed in insect cells (27). In this report we demonstrate
that Spodoptera frugiperda (Sf9) cells expressing cPLA2 can be
induced to release arachidonic acid in response to the agonists
calcium ionophore A23187 and the protein phosphatase inhib-
itor okadaic acid and that this functional response in okadaic
acid-treated cells correlates with increased phosphorylation of
a novel site on cPLA2. Evidence is also presented demonstrat-
ing that the sites phosphorylated on cPLA2 in infected Sf9 cells
also occur on cPLA2 in human monocytes.
EXPERIMENTAL PROCEDURES
Materials
Grace’s supplemented phosphate-free medium and RPMI 1640 phos-
phate-free medium were obtained from Life Technologies, Inc. RPMI
1640 medium and calcium- and magnesium-free Hanks’ balanced salt
solution were from Whittaker Bioproducts (Walkersville, MD). Se-
quencing grade, modified trypsin was from Promega. [
32P]Orthophos-
phoric acid (8,500–9,000 Ci/mmol) and [5,6,8,9,11,12,14,15-
3H]arachi-
donic acid (100 Ci/mmol) were from DuPont NEN. LPS was from List
Biological Labs (Campbell, CA). Okadaic acid and phorbol myristate
acetate (PMA) were from LC Services Co. (Woburn, MA). Zymosan,
phenylmethylsulfonyl fluoride, leupeptin, aprotinin, and A23187 were
from Sigma. Human serum albumin (HSA) was obtained from Intergen
Co. (Purchase, NY). Prior to use as a stimulus the zymosan was sus-
pended in calcium- and magnesium-free phosphate-buffered saline
(PBS) and boiled for 10 min, followed by centrifugation. After resuspen-
sion in PBS, the boiling procedure was repeated two more times. For
preparation of opsonized zymosan, the zymosan was incubated with a
1:1 dilution of human serum in 0.9% saline solution for 30 min at 37 °C
and washed once with PBS before final resuspension in PBS.
Cell Culture
Sf9 cells were grown and infected with either wild-type Autographa
californica multiply enveloped nuclear polyhedrosis virus (wild-type
virus) or recombinant A. californica multiply enveloped nuclear poly-
hedrosis virus expressing cPLA2 (recombinant virus) as described pre-
viously (24). Cell manipulations were performed at 65–70 h postinfec-
tion unless otherwise indicated. Human mononuclear cells were
purified from healthy donors on plasma/Percoll gradients (28). The
mononuclear cells were washed in calcium- and magnesium-free Hanks’
balanced salt solution and then plated at 5 3 10
6 cells/well in 12-well
plates and incubated at 37 °C in a humidified atmosphere of 5% CO2 in
air. After 1 h adherent cells were vigorously rinsed three times with
Hanks’ balanced salt solution to remove nonadherent lymphocytes, and
then 1 ml of RPMI 1640, supplemented with 10% fetal bovine serum
(FBS), 100 mg/ml streptomycin sulfate, 100 units/ml penicillin G, and
0.29 mg/ml glutamine was added. Approximately 15% of the cells ini-
tially seeded adhered to the culture dish as determined by the number
of nuclei/well using a Coulter counter.
[
3H]Arachidonic Acid Release
Sf9 cells plated at 0.5 3 10
6 cells/well in 12-well plates in 1.0 ml of
Grace’s supplemented medium containing 10% FBS were labeled with
[
3H]arachidonic acid (0.5 mCi/ml) for 18 h. The cells were rinsed three
times with Grace’s supplemented medium containing 0.1% HSA to
remove unincorporated arachidonic acid and then stimulated in Grace’s
supplemented medium containing 0.1% HSA with okadaic acid (1 mM)
or A23187 (0.5 mg/ml). After stimulation, the medium was removed and
centrifuged at 1,400 3 g for 10 min. The cells were scraped into 1 ml of
calcium- and magnesium-free PBS containing 0.1% Triton X-100. The
amount of radioactivity in the cells and media was measured by liquid
scintillation spectrophotometry.
Human monocytes were allowed to adhere for 4 h and then labeled
with [
3H]arachidonic acid (0.25 mCi/ml) in RPMI 1640 containing 10%
FBS, 100 mg/ml streptomycin sulfate, 100 units/ml penicillin G, and
0.29 mg/ml glutamine. After 16 h the cells were rinsed three times with
RPMI 1640 containing 0.25% HSA. Cells were stimulated in 1 ml of
RPMI 1640 containing 0.25% HSA with PMA (500 nM), A23187 (0.5
mg/ml), okadaic acid (1 mM), opsonized zymosan (60 particles/cell) or
LPS (1 mg/ml). After stimulation, the medium was removed and centri-
fuged at 1,400 3 g for 10 min. The cells were scraped into 1 ml of
calcium- and magnesium-free PBS containing 0.1% Triton X-100. The
amount of radioactivity in the cells and media was measured by liquid
scintillation spectrophotometry.
Phosphorylation Studies
At 20 h postinfection, Sf9 cells plated at a density of 2.5 3 10
6 cells/25
cm
2 flask were labeled for 48 h with [
32P]orthophosphoric acid (0.5
mCi/ml) in 2.5 ml of Grace’s supplemented, phosphate-free medium
containing 10% FBS, 100 mg/ml streptomycin sulfate, and 100 units/ml
penicillin G. The labeling medium was removed, and Grace’s supple-
mented phosphate-free medium containing 0.1% HSA was added. For
stimulation, okadaic acid (1 mM) or A23187 (0.5 mg/ml) dissolved in
Me2SO was added, and the cells were incubated for2ha t2 7 ° C .
Controls were incubated with Me2SO alone. After stimulation, the
medium was removed from the cells and replaced with lysis buffer (50
mM Hepes, pH 7.4, 10% glycerol, 150 mM NaCl, 1 mM EGTA, 1 mM
EDTA, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 10 mg/ml
aprotinin, 10 mg/ml leupeptin, 100 mM sodium fluoride, 3 mM p-nitro-
phenyl phosphate, 200 mM sodium orthovanadate, and 10 mM tetraso-
dium pyrophosphate). Lysates were centrifuged at 16,000 3 g, and the
supernatant was precleared with preimmune serum-coated protein A-
Sepharose beads for1ha t4° C .T h ebeads were removed by centrifu-
gation, and
32P-labeled cPLA2 was immunoprecipitated from the Sf9
cell lysates, as described below.
For
32P labeling the mononuclear cells were plated at 70 3 10
6
cells/100-mm dish, as above, allowed to adhere for 4 h, and then the
monolayer was washed three times with phosphate-free RPMI 1640.
The cells were labeled overnight with [
32P]orthophosphoric acid (1
mCi/dish) in 5 ml of phosphate-free RPMI 1640 containing 10% dialyzed
FBS, 100 mg/ml streptomycin sulfate, 100 units/ml penicillin G, and
0.29 mg/ml glutamine. Stimulants were added to the labeling medium
for 2 h. The cells were rinsed in Hanks’ balanced salt solution and
scraped into lysis buffer. The lysates were centrifuged, and the
32P-
labeled cPLA2 was immunoprecipitated from the monocyte cell lysates,
as described below.
Phosphorylation of cPLA2 in Vitro with MAP Kinase
To 30 mg of cPLA2 in 50 mM Tris, 100 mM NaCl, 0.1 mM EDTA, 0.1 mM
EGTA, 10 mM MgCl2, 140 mM ATP, 10 mCi [g-
32P]ATP (3,000 Ci/mmol,
DuPont NEN), pH 8.0, was added 60 ng of recombinant MAP kinase
(obtained as a generous gift from Prof. E. Krebs, University of Wash-
ington), and the mixture was incubated for 2.5 h at room temperature.
Radiolabeled cPLA2 was submitted to electrophoresis on a Laemmli gel,
and the protein was eluted from the gel and digested with trypsin as
described below. The digest was submitted to HPLC (218TP52 column)
as described below, and fractions containing cpm in the peak 4 region
(see Fig. 4) were pooled. Most of the solvent was removed in a Speed-Vac
concentrator (Savant Instruments), and half of the sample was submit-
ted to two-dimensional peptide mapping. The remaining half was con-
centrated to dryness in a Speed-Vac, and the residue was oxidized with
30 ml of performic acid reagent, diluted with 50 ml of water, and
lyophilized as described (29). The oxidized peptide was dissolved in 5 ml
of glacial acetic acid, and the sample was submitted to two-dimensional
peptide mapping.
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32P-Labeled cPLA2
Sf9 and monocyte cell lysates were incubated with polyclonal anti-
serum (11683) generated as described previously against recombinant
cPLA2 at either a 1:7.5 or a 1:500 dilution, respectively, for 16 h at 4 °C
(24). Protein A-Sepharose beads were added and the mixture tumbled
f o r2ha t4° C .T h ecPLA2 was recovered by centrifugation at 4 °C. The
beads were washed five times in lysis buffer and then boiled in 2 3
Laemmli buffer containing 40 mM dithiothreitol (30). The eluted cPLA2
was separated on a 7.5% SDS-polyacrylamide gel, the gel was dried, and
the cPLA2 band was visualized by autoradiography.
Preparation of Tryptic Peptides for HPLC and
Two-dimensional Peptide Maps
32P-Labeled cPLA2 was excised from dehydrated SDS-polyacryl-
amide gels, and two to three gel pieces were homogenized in 1.2 ml of 50
mM ammonium bicarbonate containing 0.08% SDS and 1% 2-mercap-
toethanol (elution buffer). The samples were boiled for 5 min and then
tumbled for 16 h at room temperature. Gel pieces were separated from
eluant by centrifugation, another 300 ml of elution buffer was added to
the gel pellet, and the sample was rocked2ha troom temperature. The
second eluant was collected by centrifugation, combined with the first,
and the volume per tube was reduced in a Speed-Vac to 200 ml. The
amount of cPLA2 recovered from Sf9 cell lysates was estimated by
comparison with known amounts of purified recombinant cPLA2 (deter-
mined by measuring the absorbance at 280 nm) on Coomassie-stained,
SDS-polyacrylamide gels (24). Unlabeled recombinant cPLA2 (5 mg) was
added to monocyte samples as carrier protein. The cPLA2 was precipi-
tated from elution buffer by the addition of 30 ml of 100% trichloroacetic
acid. The tubes were incubated on ice for 2 h, the trichloroacetic acid
precipitate was collected by centrifugation in a microcentrifuge at full
speed for 10 min at 4 °C, washed two times with ice-cold acetone by
centrifugation as above, and the residual acetone was removed with a
stream of N2. Based on Cerenkov counting, the yield of precipitated
cPLA2 was greater than 90%. The precipitate was resuspended in 200
ml of freshly made 50 mM ammonium bicarbonate, pH 7.8–8.2, and
trypsin was added at a trypsin:cPLA2 ratio of 1:10 by weight. The
samples were incubated for3ha t3 7° Ca n dthen stored at 220 °C. The
amount of trypsin in the stock solution was assayed each time it was
used. A tube containing 20 mg of lyophilized trypsin, as supplied by
Promega, was hydrated with 100 ml of Promega trypsin dilution buffer.
One ml of 50 mM Tris-HCl, 1 mM CaCl2, pH 7.6, was placed in a cuvette,
and 4.8 ml of benzoyl-arginine ethyl ester solution (100 mM) was added.
The cuvette was placed in the thermostatted holder of the spectropho-
tometer, and the absorbance at 253 nm was recorded at 29 °C until the
base line was flat. Three ml of trypsin solution was added to the assay,
and the absorbance at 253 nm was monitored for several minutes. The
typical response from this 0.6-mg portion of trypsin was 0.036 absorb-
ance/min, and this specific activity was used to determine the amount
of trypsin in other stock solutions. Trypsin stock solutions were stored
at 220 °C, and working solutions were kept at 4 °C for no more than a
few hours. Cerenkov counting revealed that greater than 90% of the
cpm became solubilized following proteolysis.
Two-dimensional Phosphopeptide Mapping
Ammonium bicarbonate buffer was removed from the tryptic digests
by the addition of 500 ml of water, and then the sample was dried in a
Speed-Vac. Water was added again, and the process was repeated two
more times. The sample was then resuspended in glacial acetic acid or
buffer 1, pH 1.9 (acetic acid, 88% formic acid, H2O) (78:25:897, v/v/v).
The sample was subjected to thin layer electrophoresis on 20 3 20-cm
Kodak cellulose thin layer chromatography plates. Electrophoresis in
the first dimension was performed at 1,400 V for 20 min in ammonium
carbonate buffer, pH 8.9 (10 g of ammonium carbonate/liter), using a
Hunter Thin Layer Peptide Mapping System (CBS Scientific, Del Mar,
CA). The plate was air dried at room temperature overnight and then
subjected to ascending chromatography in isobutyric acid:pyridine:ace-
tic acid:butanol:H2O (65:5:3:2:29, v/v/v/v). The plate was then air dried
and subjected to autoradiography.
Phosphoamino Acid Analysis
A tryptic digest of immunoprecipitated cPLA2 was digested in 100 ml
of 6N H C lf o r1ha t1 1 0° C .T h eH C lw a sremoved in a Speed-Vac, and
the pellet was redissolved in buffer 1, pH 1.9. A mixture of phospho-
serine, phosphothreonine, and phosphotyrosine (5 mg of each) was
added. The samples were analyzed by ascending chromatography on
Merck 20 3 20-cm cellulose thin layer chromatography plates with
butanol:acetic acid:ethanol:H2O (1:1:1:1, v/v/v/v) (18). Phosphoamino
acids were visualized by spraying the plates with a solution of 0.2%
ninhydrin in acetone (w/v), and
32P-labeled phosphoamino acids were
identified by autoradiography.
Purification of Tryptic Phosphopeptides for Analysis by
Micro-LC/MS, MALDI-TOF, and Edman Sequencing
Trypsin-digested,
32P-labeled cPLA2 was injected onto an HPLC col-
umn (Vydac 218TP52 or 218HS52, 0.21 3 25 cm), and the column was
developed at a flow rate of 0.15 ml/min with 100% solvent A (0.06%
CF3COOH in water (Milli-Q, Millipore)) for 15 min, to 30% solvent B
(0.06% CF3COOH in CH3CN (Baker HPLC grade)) over 60 min, to 60%
solvent B over 30 min, to 100% solvent B over 10 min, and finally
holding at 100% solvent B. Peptides were detected by monitoring the
absorbance at 210 nm. Fractions were collected into silanized polypro-
pylene microcentrifuge tubes (VWR 20172-935) and were stored at
220 °C prior to further analysis. These tubes were also used for all
manipulations of the HPLC fractions, and Cerenkov counting was used
at all stages of the analyses to gauge the solubility of the tryptic
phosphopeptides.
HPLC Peak 1—Trypsinized, radiolabeled cPLA2 from unstimulated
Sf9 cells (30 mg, 142,000 cpm) was injected onto the HPLC column
(218TP52), and fractions containing radioactivity in the peak 1 region
(see Fig. 4) were pooled. The solution was concentrated to 30 mli na
Speed-Vac concentrator, 400 ml of water was added, and this process
was repeated twice; the final volume was adjusted to 100 ml. Three mlo f
the sample was injected onto the micro-LC/MS. Some of this sample (10
ml) was esterified with ethanol as follows. The sample was concentrated
to dryness in a Speed-Vac, and 20 ml of HCl/ethanol was added. After 2
h at room temperature, 10 ml of 0.5% acetic acid was added, and 5 mlo f
sample was injected onto the LC/MS. The esterification reagent was
prepared by adding 160 ml of acetyl chloride dropwise to 1 ml of ethanol
with stirring, and after 5 min at room temperature the reagent was
used. Purified water (Milli-Q) was used in all subsequent manipula-
tions of the HPLC fractions.
HPLC Peak 3—Trypsinized, radiolabeled cPLA2 from okadaic acid-
treated Sf9 cells (690 mg, 116,000 cpm) was injected in two portions onto
the HPLC column (218TP52), and fractions containing radioactivity in
the peak 3 region (see Fig. 4) from both runs were pooled. Solvent was
removed in a Speed-Vac. To the residue was added 60 ml of glacial acetic
acid, the tube was gently shaken, and 0.5 ml of water was added. The
mixture was immediately injected onto the 218HS52 column. Virtually
all of the cpm eluted in a single peak at 80.5 min. The cpm-containing
fractions were pooled, and solvent was removed in the Speed-Vac. To
the residue was added 2 ml of glacial acetic acid followed by 18 mlo f
water, and 2 ml was injected onto the micro-LC/MS. A portion (1–2 ml)
was also analyzed by positive ion MALDI-TOF using the instrument
described previously (31). The sample was deposited on the sample slide
and mixed with an equal volume of a-cyano-4-hydroxycinnamic acid
reagent (5 mg/ml in acetonitrile, 0.1% aqueous trifluoroacetic acid
(1:2)).
HPLC Peak 2—Trypsinized, radiolabeled cPLA2 from okadaic acid-
treated Sf9 cells (900 mg, 240,000 cpm) was injected in three portions
onto the HPLC column (218HS52), and fractions containing radioactiv-
ity in the peak 2 region (see Fig. 4) from two of the runs were pooled.
Peak 2 fractions from the third HPLC run were stored at 220 °C and
were not used further. Solvent was removed from the two tubes of
pooled fractions in a Speed-Vac, and to each tube was added 20 mlo f
glacial acetic acid. After gentle mixing, each sample was spotted onto a
separate cellulose plate. To ensure complete transfer onto the plate, a
second portion of acetic acid (10 ml) was added to each tube, and this
material was transferred to the plates. The plates were submitted to
electrophoresis and ascending chromatography as described above.
Prior to autoradiography (3-h exposure), the plates were air dried
overnight at room temperature. The region of each plate containing the
radioactive material was scraped with a razor blade, and the cellulose
powder was transferred to a microcentrifuge tube. To the cellulose
powder from each of the two samples was added 0.5 ml of buffer 1, pH
1.9, the tubes were mixed by vortexing for 2 min and microcentrifuged
for 15 min. The supernatants were transferred to new tubes, and this
extraction procedure was repeated. After combining the supernatants,
the solvent was reduced to 40–50 ml in each sample in a Speed-Vac, and
the samples were stored at 220 °C. Each tube contained about 1,200
cpm. Micro-LC/MS was carried out by mixing a 3–4-ml aliquot of two-
dimensional map-purified peptide with 5 ml of 0.5% acetic acid and
injecting 6 ml of the mixture onto the instrument. Purified material was
also analyzed by MALDI-TOF.
A portion of this two-dimensional peptide map-purified phosphopep-
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coupled to a Sequelon-AA membrane (MilliGen) according to the pro-
cedure provided by the manufacturer. The membrane disc was washed
with two 1-ml portions of methanol, and 200 cpm of peptide remained
on the disc, which was stored at 220 °C for a few days. The disc was
placed in the reaction vessel of a 477A Sequencer (Applied Biosystems).
Sequencing reaction cycles were carried out with standard reagents and
conditions except that the S3 wash, which is usually n-butyl chloride,
consisted of 2 mM NaH2PO4 in methanol:water (9:1), pH 7 (not adjust-
ed). The entire S3 wash from each cycle was diverted into glass vials.
Micro-LC
The HPLC grade solvents methanol, acetonitrile, and acetic acid
were purchased from Fisher Scientific. Microcolumns were made by
employing 98-mm inner diameter fused silica capillary tubing obtained
from Polymicro Technologies (Tucson, AZ) (32). The columns were
packed with PerSeptive Biosystems (Boston) POROS 10 R2, a 10-mm
reverse-phase packing material, to a length of 15–20 cm. Samples were
injected onto the column using a high pressure packing device, as
described previously (32). Micro-LC was performed using Applied Bio-
systems 140B dual syringe pumps. The flow rate from the pumps was
100 ml/min. The solvent stream was split, ;50:1, precolumn, to produce
a final flow rate of 1–2 ml/min. After loading the sample the column was
washed with 100% solvent A (0.5% acetic acid) for 5 min. The peptides
were eluted with a linear gradient of 0–80% B (80% acetonitrile, 20%
water in 0.5% acetic acid) in 15, 30, or 60 min. The outlet of the column
was inserted directly into the electrospray needle.
Electrospray Ionization Mass Spectrometry
Mass spectra were recorded on a Finnigan MAT (San Jose, CA)
TSQ700 equipped with an electrospray ionization source as described
previously (33). Electrospray ionization was performed using the fol-
lowing conditions. The needle voltage was set at 4.6 kV. The sheath and
auxiliary gases consisted of nitrogen gas (99.999%) and were set at
20–25 p.s.i. and 5–10 units, respectively. The heated capillary temper-
ature was set at 150 °C. A sheath liquid flowed around the end of the
column at a flow rate of 1.5 ml/min and was a methanol:water (70:30)
mixture containing 0.1% acetic acid.
Mass spectra were acquired as peptides eluted from the LC by
scanning Q3 at a rate of 500 u/s over the range 400-1,500 m/z. Peak
widths ranged from 1.5 to 2.0 u. Signal was detected with a conversion
dynode/electron multiplier. Sequence analysis of peptides was per-
formed during a second HPLC analysis by selecting the precursor ion
with a 2–3-u (full width at half height) wide window in the first mass
analyzer and passing the ions into a collision cell filled with argon to a
pressure of 3–4 millitorr. Collision energies were on the order of 10–50
eV (Elab). The fragment ions produced in Q2 were transmitted to Q3,
which was scanned at 500 u/s over a mass range of 50 u to the molecular
weight of the precursor ion to record the fragment ions. Peak widths in
the second mass analyzer ranged from 1.5 to 2.0 u. The electron mul-
tiplier setting was 200–400 V higher than that used to record the
molecular weight.
Data Base Searching
Amino acid sequence data bases were searched directly with tandem
mass spectra by a computer algorithm previously described (34–36). All
computer algorithms were written on a DEC station 5000/200 computer
by using the C programming language under the Ultrix operating
system. The OWL data base, version 24.0, was obtained as ASCII text
files in the FASTA format from the National Center for Biotechnology
Information (NCBI) by anonymous file transfer protocol. A species-
specific data base was created by removing the protein sequences de-
rived from Homo sapiens to create subsets of the OWL.
RESULTS
Stimulated Arachidonic Acid Release by Sf9 Cells Expressing
cPLA2—Previous studies have demonstrated that cPLA2 is ex-
pressed to 3–5% of the cellular protein in Sf9 insect cells using
the baculovirus expression system, and the enzyme is phospho-
rylated on Ser-505, the MAP kinase consensus site (24, 27, 37).
Experiments were carried out to determine if this expression
system could be used to study the regulation of cPLA2 activity.
Sf9 cells were found to readily incorporate radiolabeled arachi-
donic acid into membrane phospholipid. When Sf9 cells were
infected with recombinant baculovirus containing cPLA2 and
then labeled with [
3H]arachidonic acid, the cells could be stim-
ulated to release arachidonic acid with either A23187 or oka-
daic acid (Fig. 1). The degree of stimulated arachidonic acid
release correlated with the level of cPLA2 expression which we
have previously demonstrated is maximal between 48 and 67 h
postinfection (24). In contrast, when Sf9 cells were infected
with wild-type baculovirus there was only a small increase in
arachidonic acid release in response to A23187 treatment, but
the degree of release did not change at different times after
infection. Consequently, the stimulated release of arachidonic
acid in Sf9 cells infected with recombinant virus could be at-
tributed to the specific activation of cPLA2 by either A23187 or
okadaic acid. The time course of [
3H]arachidonic acid release in
response to A23187 and okadaic acid from Sf9 cells expressing
cPLA2 is shown in Fig. 2. An increase in arachidonic acid
release above control levels could be detected 15 min after
treatment with either A23187 or okadaic acid. The label con-
tinued to accumulate gradually in the medium up to 2 h after
A23187 treatment reaching 3-fold the control levels. A greater
level of free arachidonic acid, 7–8 times the level in unstimu-
lated cells, was released in the medium up to 2–4 h after
okadaic acid treatment.
Phosphorylation of cPLA2 in Sf9 Cells—It has been demon-
strated that site-specific phosphorylation of cPLA2 by MAP
kinase reduces its electrophoretic mobility on SDS gels (21).
cPLA2 expressed in unstimulated Sf9 cells 67 h after viral
infection runs as a doublet on a SDS-polyacrylamide gel, with
approximately equal amounts in both forms (Fig. 3). Treatment
with A23187 did not affect this pattern, whereas okadaic acid
induced a complete gel shift. The ability of okadaic acid to
induce a complete gel shift suggests a correlation of cPLA2
phosphorylation with activation of cPLA2 leading to arachi-
donic acid release. To explore further the role that phosphoryl-
ation plays in cPLA2 activation in this model system, the phos-
phorylation sites in control and okadaic acid-treated Sf9 cells
were identified.
HPLC Analysis of Tryptic Phosphopeptides from cPLA2 Ex-
pressed in Sf9 Cells—A typical HPLC profile of tryptic peptides
(absorbance at 210 nm) and phosphopeptides (cpm) of
32P-
labeled cPLA2 from okadaic acid-stimulated Sf9 cells is shown
in Fig. 4. Four major peaks of radioactivity were seen. The
distribution of counts in the four peaks obtained from cPLA2
immunoprecipitated from unstimulated Sf9 cells and the
change in labeling of the peaks in response to agonist treat-
FIG.1 . [
3 H]Arachidonic acid release from Sf9 cells. Sf9 cells
were infected with either wild-type virus (panel A) or recombinant virus
containing the gene for cPLA2 (panel B). Cells were labeled with
[
3H]arachidonic acid 18 h prior to the addition of stimuli. At the indi-
cated times postinfection [
3H]arachidonic acid-labeled Sf9 cells were
treated with A23187 (0.5 mg/ml, solid bars), okadaic acid (1 mM, striped
bars), or vehicle (0.1% Me2SO, open bars)f o r2h .
3 H label released into
the medium is expressed as a percent of the total radioactivity (cell
associated plus media). The results are expressed as mean 6 S.D. of
triplicate values from a representative experiment.
Phosphorylation Sites on Cytosolic Phospholipase A2 6990ment are shown in Table I. Peaks 1 and 4 were the major
32P-labeled phosphopeptides of cPLA2 from unstimulated cells.
Treatment of Sf9 cells with A23187 induced only a small in-
crease in labeling of the peptides. The most dramatic change
was observed after stimulation with okadaic acid, which re-
sulted in a 4.5-fold increase in
32P labeling of peak 2. Only
small increases in labeling of peaks 1, 3, and 4 occurred in
response to okadaic acid. In a few HPLC runs, a small peak of
radioactivity preceded peak 4 by 6 min (not shown). As de-
scribed below, this peak is an oxidized derivative of peak 4.
Importantly, the total cpm eluted from the HPLC column was
typically 70–80% of that applied, and ,0.5% of the cpm eluted
in the void volume. In addition, greater than 90% of the cPLA2-
associated cpm was solubilized following trypsinization. The
fact that yields of cpm are high in all steps rules out the
possibility that a major phosphopeptide was lost during sample
manipulations.
The
32P-labeled tryptic phosphopeptides were also analyzed
on two-dimensional phosphopeptide maps. A representative
phosphopeptide map of
32P-labeled cPLA2 from okadaic acid-
treated Sf9 cells is shown in Fig. 5. Five major spots were
observed. To determine the correspondence between the HPLC
peaks and the spots on the two-dimensional peptide maps, each
of the HPLC-purified phosphopeptides derived from cPLA2 ex-
pressed in Sf9 cells was individually analyzed by two-dimen-
sional peptide mapping. Since phosphopeptide spots 1, 2, and 3
run close together, pairs of HPLC peaks (1 1 2, 1 1 3, and 2 1
3) were also analyzed by two-dimensional phosphopeptide
mapping to make the assignments unequivocal. In this way
phosphopeptide spots 1–4 were assigned. There still remained
a significant phosphopeptide spot near spot 1 (labeled 5 in Fig.
5) which had no corresponding peak in the HPLC. Since HPLC
peaks 1–4 account for virtually all of the eluted cpm, it was
suspected that phosphopeptide spot 5 was the result of decom-
position of one or more phosphopeptides during analysis. This
was indeed the case. The intensity of spot 5 relative to its
neighboring spot 1 was highly variable in independent analy-
ses. When spot 5 was eluted from the cellulose plate and then
injected onto the HPLC column, all of the cpm eluted in the
void volume, and as described above, virtually no cpm was
detected in the void volume of trypsin-digested cPLA2 that was
injected onto HPLC without prior submission to two-dimen-
sional peptide mapping. Further evidence indicated that phos-
phopeptide spot 5 comes completely from phosphopeptide 1.
When the phosphopeptide spot 1 was eluted from the cellulose
plate and reanalyzed by two-dimensional peptide mapping,
both spot 1 and 5 were seen. The nature of this decomposition
was not investigated further.
Identification of cPLA2 Phosphorylation Sites by Mass Spec-
trometry—Analysis of HPLC peak 1 material by micro-LC/MS
showed several peptides (data not shown). The most prominent
ion was accompanied by another ion 33 u smaller, which is
indicative of the loss of neutral phosphoric acid from a triple-
charged ion. The loss of phosphoric acid is often seen in phos-
phoserine- and phosphothreonine-containing peptides and is
thus used as a marker for phosphopeptides (however, see be-
low). The observed molecular weight of this putative phos-
phopeptide, 2,079 (not shown), is consistent with the tryptic
peptide of amino acid residues 428–445 from cPLA2 containing
a single phosphate. To confirm the identity of this peptide and
to locate the phosphorylation site, micro-LC/MS/MS analysis
was carried out. The resulting product ion spectrum (not
shown) was sufficient to confirm the identity of the peptide and
to narrow down the site of phosphorylation to either Ser-435 or
Ser-437. However, it was not possible to determine confidently
which of these two serines was phosphorylated, although the
FIG.2 .Time course of [
3H]arachidonic acid release from Sf9
cells. [
3H]Arachidonic acid-labeled Sf9 cells infected with recombinant
virus were stimulated at 67 h postinfection for the times indicated with
A23187 (0.5 mg/ml, L), okadaic acid (1 mM, E), or vehicle (0.1% Me2SO,
M).
3H label released into the media is expressed as a percent of the
total radioactivity (cell associated plus media). The results are ex-
pressed as the mean 6 S.D. of triplicate values from a representative
experiment.
FIG.3 .Effect of stimulation of Sf9 cells on mobility of recom-
binant cPLA2 on a SDS-polyacrylamide gel. Sf9 cells infected with
recombinant virus were stimulated at 67 h postinfection for 2 h with
Me2SO (0.1%), A23187 (0.5 mg/ml), or okadaic acid (1 mM). Cell lysates
(400 ng/lane) were separated on a 10% SDS-polyacrylamide gel pre-
pared as described previously (24). Immunoblots were incubated with a
polyclonal antibody against the recombinant cPLA2, and the Amersham
ECL system was used for detection.
FIG.4 .HPLC of tryptic peptides de-
rived from cPLA2 from okadaic acid-
stimulated Sf9 cells. After trypsiniza-
tion of trichloroacetic acid-precipitated
cPLA2, the digest was applied to a C18
reverse-phase HPLC column (Vydac
218TP52). Other details are given under
“Experimental Procedures.” Eluted cpm
were determined by Cerenkov counting
(dotted line), and the peptide elution was
monitored by absorbance at 210 nm.
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on the Ser-437. This is because the predicted b-type and y-type
product ions that are different between the the Ser-435 versus
the Ser-437 were not observed, and such a negative result
cannot be used as definitive proof of structure. Thus, the HPLC
peak 1 phosphopeptide was treated with ethanol/HCl to con-
vert all of its carboxyl groups to ethyl esters. The micro-LC/
MS/MS analysis is shown in Fig. 6A, and the site of phospho-
rylation was identified as Ser-437. The y ions, y1–y9, are
observed, and at Ser-437 the mass of the y series increases by
80 u, consistent with a phosphate on Ser-437. The y ions y9–y12
and the double-charged y ions, y15–y17, show the characteristic
loss of neutral phosphoric acid. The b ions, b5–b9, are also
observed, as well as a series of b ions resulting from the loss of
phosphoric acid (b10–b12).
Analysis of HPLC peak 3 by MALDI-TOF gave two major
peaks of molecular weights 2,483 and 2,562 (not shown). These
differ in mass by 79, suggesting that the lighter peptide is the
nonphosphorylated version of the heavier peptide. The mass
corresponds to the tryptic peptide 446–467. Analysis of this
material by micro-LC/MS also showed the presence of these
two peptides. Only a very weak neutral loss ion was seen for
the phosphopeptide. The micro-LC/MS/MS spectrum of the pu-
tative phosphopeptide is shown in Fig. 6B. A series of y ions,
y1–y11, as well as a series of double-charged y ions, y5–y21, was
seen, indicating that Ser-454 is phosphorylated. Loss of phos-
phoric acid from double-charged y ions, y15–y21, was observed.
Analysis of HPLC peak 2 by micro-LC/MS was problematic
in that this HPLC fraction contained multiple peptides, and no
major peak was accompanied by a fragment resulting from the
neutral loss of phosphoric acid. Furthermore, no pair of peaks
that differed by the mass of the phosphate group was found.
However, phosphoamino acid analysis of
32P-labeled peak 2
material confirmed that phosphoserine was present (Fig. 7,
lane 2). Consequently, HPLC peak 2 material was purified
further by HPLC and two-dimensional peptide mapping (see
“Experimental Procedures”). Even after further purification, a
candidate phosphopeptide could not be identified. As a result,
the peptide was submitted to automated Edman sequencing.
This analysis revealed a major component that was identified
as the tryptic peptide starting at residue 446, which suggests
that it is the tryptic peptide 446–467. Analysis of the original
micro-LC/MS data set revealed the presence of this peptide in
its nonphosphorylated form. Thus, remarkably, HPLC peak 2
material is contaminated with HPLC peak 3 material even
after extensive purification. The sequencing also revealed a
minor component with the sequence QNPSXXXVSLSNVEAX,
where X designates amino acids that could not be identified in
the sequencing cycle. The sequencing data suggested that this
peptide (721–736) is the result of incomplete trypsin digestion.
The original micro-LC/MS data set was analyzed for the pres-
ence of this peptide and its phosphorylated derivative. Al-
though ions corresponding to this peptide were not observed, a
major peptide in the mixture had a mass corresponding to the
721–736 peptide with one phosphate and three additional oxy-
gens (calculated 1,876.0 from the observed m/z values of the 12
and 13 ions of 626 and 939, respectively). It should be stressed
that no loss of phosphoric acid was seen from this peptide. The
mass data suggested that the cysteine residue of the 721–736
peptide had become oxidized during isolation. A major peak of
mass 1,876.2 was also seen in the MALDI-TOF analysis of this
phosphopeptide (not shown). Fig. 6C shows the micro-LC/
MS/MS spectrum of the 13 ion. The y ions y1–y14 were ob-
served, and the series indicates that Ser-727 is phosphorylated.
An incomplete series of b ions was observed, as well as frag-
ments that are the result of multiple losses of water and am-
monia. This b ion series is also consistent with Ser-727 as the
phosphorylation site since the high negative charge near the
internal trypsin cleavage site is probably the reason that tryp-
sin did not cleave at this site. Finally, an authentic sample of
the Ser-727 phosphopeptide was prepared by oxidation (29) of
a machine-synthesized phosphopeptide and was found to have
the same HPLC retention time as cPLA2-derived peak 2.
Data Base Searching—The MS/MS spectra in Fig. 6, A-C,
were used to search the human protein sequence data base of
17,903 entries (see “Experimental Procedures”) using the algo-
rithm SEQUEST. This procedure resulted in the correct iden-
tification of the three cPLA2 phosphopeptides described above
as well as their correct phosphorylation sites.
MAP Kinase Phosphorylation Site—Previous studies have
shown that cPLA2 expressed in Sf9 cells is phosphorylated at
its MAP kinase site (Ser-505) (37). To determine which, if any,
of the HPLC peaks 1–4 is the MAP kinase-phosphorylated
tryptic peptide, purified cPLA2 was phosphorylated in vitro
with recombinant MAP kinase (see “Experimental Proce-
dures”). HPLC analysis of the trypsin digest revealed a major
peak of radioactivity which comigrated exactly with peak 4
material from the cPLA2 phosphorylated in Sf9 cells (not
FIG.5 .Two-dimensional tryptic phosphopeptide maps of
32P-
labeled recombinant cPLA2 from Sf9 cells. A tryptic digest of
immunoprecipitated, gel-purified recombinant cPLA2 from okadaic ac-
id-stimulated Sf9 cells was separated by two-dimensional phosphopep-
tide mapping as described under “Experimental Procedures.” Phos-
phopeptides were detected by autoradiography. The sample was spotted
at the position marked by E. Electrophoresis was run in the horizontal
dimension, with the anode on the left, and chromatography was run in
the vertical dimension. Phosphopeptides are labeled 1, HPLC-purified
tryptic peptide 1; 2, peptide 2; 3, peptide 3; 4, peptide 4 and were
identified by comigration with HPLC-purified tryptic peptides (see
“Results” for a description of spot 5).
TABLE I
32P-Labeling pattern of tryptic phosphopeptides of recombinant
cPLA2 from stimulated and unstimulated Sf9 cells
Tryptic digests of
32P-labeled recombinant PLA2 from unstimulated,
A23187-stimulated, and okadaic acid-stimulated Sf9 cells were sepa-
rated by HPLC. Fractions were collected and radioactivity determined
by Cerenkov counting. Data represent the mean 6 S.E. from three
separate experiments.
Distribution of
32P label in
phosphopeptides
a Increase of
32P label in
phosphopeptides
a
Peaks Unstimulated A23187 Okadaic acid
% -fold
14 9 6 4 1.4 6 0.2 1.3 6 0.3
27 6 2 1.5 6 0.2 4.5 6 0.8
39 6 2 1.2 6 0.1 1.6 6 0.3
43 4 6 3 1.3 6 0.1 1.4 6 0.1
a The cpm from the different HPLC runs were normalized to a con-
stant mass of trypsinized cPLA2. The latter was obtained from the peak
areas of the 210 nm absorbance trace for each HPLC run.
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tion mass spectra recorded on ions
generated from cPLA2 tryptic pep-
tides. Fragments of types b and y having
the general formulas H(NHCHRCO)n
1
and H2(NHCHRCO)nOH
1, respectively,
are shown above and below the amino
acid sequence at the top of the figure. In
addition, double-charged y ions are also
shown. All ions correspond to average
masses. Ions observed in the mass spec-
trum are underlined, and ions resulting
from neutral loss of phosphoric acid are
shown in boldface type. The serine in
boldface type was determined to be phos-
phorylated. Leu and Ile were assigned by
correspondence to the known sequence. In
the spectrum, ions resulting from neutral
loss of phosphoric acid are denoted by 2P.
Panel A, collision-induced dissociation
mass spectrum recorded on the
(M13H)
13 ions at m/z 759 of a tryptic
fragment, residues 428–445, in the ethyl-
ester form. Panel B, collision-induced dis-
sociation mass spectrum recorded on the
(M13H)
13 ions at m/z 854 of a tryptic
fragment, residues 446–467. Only resi-
dues 446–463 are shown at the top of the
figure. Panel C, collision-induced dissoci-
ation mass spectrum recorded on the
(M12H)
12 ions at m/z 939 of a tryptic
fragment, residues 721–736. In the spec-
trum, asterisks are used to denote single
or multiple neutral losses of water (or am-
monia) from an ion.
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peak 4 material when analyzed on two-dimensional peptide
maps. Phosphoamino acid analysis showed that peak 4 mate-
rial contained phosphoserine (Fig. 7, lane 1). Repeated at-
tempts to confirm the structure of this in vitro phosphorylated
MAP kinase peptide by micro-LC/MS were unsuccessful. How-
ever, MALDI-TOF analysis of this material revealed a major
signal at mass 5,107, which agrees well with the calculated
mass of 5,114 for this tryptic phosphopeptide. It is clear from
this analysis that HPLC peak 4 is the MAP kinase-phosphory-
lated tryptic peptide (residues 489–533).
Phosphorylation of cPLA2 in Human Monocytes—cPLA2
plays a key role in releasing arachidonic acid for prostaglandin
production in human monocytes, and previous studies revealed
that monocyte cPLA2 is regulated by phosphorylation (2, 38).
Therefore, monocytes were used to determine if similar sites
were phosphorylated on cPLA2 in a mammalian system, as
identified on the cPLA2 expressed in Sf9 cells. Experiments
were initially carried out to compare the effect of a variety of
agonists on inducing arachidonic acid release (Fig. 8A). In
response to A23187, LPS, and opsonized zymosan, arachidonic
acid accumulated in the medium at a linear rate up to 1 h after
stimulation and then started to plateau. Release of arachidonic
acid with okadaic acid and PMA showed an initial lag com-
pared with the other stimuli. The ability of each stimulus to
induce a shift in electrophoretic mobility of the cPLA2 on im-
munoblots was also investigated (Fig. 8B). Most of the cPLA2
from unstimulated monocytes migrated on the gel as the faster
migrating form, although a small amount of the phosphoryl-
ated form was present, and this varied depending on the donor.
After stimulation with PMA, okadaic acid, LPS, or zymosan,
the majority of the monocyte cPLA2 shifted to the slower mi-
grating phosphorylated form, whereas A23187 caused a
smaller portion of the cPLA2 to gel shift.
Monocytes were
32P labeled and stimulated with okadaic
acid and opsonized zymosan to determine if agonist treatment
induced an increase in phosphorylation of the cPLA2. Incuba-
tion with okadaic acid for 2 h induced a 2.5 6 0.97-fold (mean
6 S.E., three experiments) increase in phosphorylation of the
cPLA2, whereas in one experiment opsonized zymosan in-
creased phosphorylation by 2.7-fold. Phosphoamino acid anal-
ysis showed that phosphorylation occurred exclusively on ser-
ine residues in unstimulated and okadaic acid-stimulated
monocytes (Fig. 7, lanes 3 and 4). Initial attempts to obtain
enough
32P-labeled monocyte cPLA2 to prepare tryptic digests
for HPLC to compare with cPLA2 phosphorylated in Sf9 cells
were unsuccessful because of inefficient labeling of the mono-
cyte cPLA2. Consequently, tryptic phosphopeptides of the
32P-
labeled cPLA2 from monocytes and Sf9 cells were compared by
two-dimensional phosphopeptide mapping. The migration pat-
tern of the phosphopeptides derived from monocyte cPLA2 was
similar to that of phosphopeptides derived from recombinant
cPLA2 except for novel phosphopeptides that appeared in
monocyte samples in the spot 7 region. Two principal phos-
phopeptides, 4 and 7, were observed on peptide maps of tryptic
digests of cPLA2 derived from unstimulated monocytes (Figs.
9A and 10A). After stimulation with okadaic acid phosphopep-
tide 2 became very prominent, and new phosphopeptides, 3 and
6, appeared (Fig. 9B). After zymosan stimulation phosphopep-
tides 4 and 7 were most prominent, and also evident were
phosphopeptides 2 and 6 (Fig. 10B). The yields of phosphopep-
tides transferred from the tubes to the cellulose plates as
gauged by Cerenkov counting were variable, and thus the
increases in the phosphorylation of the phosphopeptides on the
maps could only be considered in a qualitative manner. The
yields were nearly quantitative and consistent in the HPLC
separations, and only these data were used for obtaining quan-
titative data after stimulation. To confirm the identity of the
monocyte phosphopeptides, samples from stimulated mono-
cytes were cospotted with samples from okadaic acid-stimu-
lated Sf9 cells (Figs. 9D and 10D). Comparison of the maps
with the cospotted samples with the maps of the samples run
alone showed that the phosphopeptides 2, 3, and 4 derived from
monocyte cPLA2 comigrated with those derived from cPLA2
expressed in Sf9 cells. In addition, weak spots in the 1 and 5
positions were seen in the sample from zymosan-stimulated
monocytes. Spot 7 is probably an oxidized derivative of the
MAP kinase peptide (spot 4). This spot was seen only on some
of the phosphopeptide maps. In addition, oxidation of pure
phosphopeptide 4, which was eluted from the cellulose plate,
with performic acid gave rise to material that migrated in the
FIG.7 .Phosphoamino acid analysis. HPLC-purified
32P-labeled
tryptic peptides derived from cPLA2 from okadaic acid-stimulated Sf9
cells (lane 1, peak 4; lane 2, peak 2) or
32P-labeled tryptic digests
derived from cPLA2 from human monocytes (lane 3, unstimulated
monocytes; lane 4, okadaic acid-stimulated monocytes) were hydrolyzed
with HCl and separated along with phosphoserine (PS), phosphothreo-
nine (PT), and phosphotyrosine (PY) standards on cellulose thin layer
plates as described under “Experimental Procedures.” Phosphoamino
acid standards were visualized with ninhydrin, and the
32P-labeled
phosphoamino acids were detected by autoradiography.
FIG.8 .Effect of stimulation of human monocytes on [
3H]arac-
hidonic acid release and on the mobility of cPLA2 on a SDS-
polyacrylamide gel. Panel A,[
3 H]arachidonic acid-labeled monocytes
were incubated with Me2SO (0.1%, M), okadaic acid (1 mM, ), LPS (1
mg/ml, f), PMA (500 nM, E), opsonized zymosan (60 particles/cell, l), or
A23187 (0.5 mg/ml, L) for the indicated times.
3H label released into the
media is expressed as a percent of the total radioactivity (cell associated
plus media). The results are the average of duplicate values from a
representative experiment. Panel B, monocytes were stimulated for 2 h
with Me2SO (0.1%), okadaic acid (1 mM), LPS (1 mg/ml), PMA (500 nM),
opsonized zymosan (60 particles/cell), or A23187 (0.5 mg/ml). Cell ly-
sates (20 mg/lane) were separated on a 7.5% SDS-polyacrylamide gel.
Immunoblots were incubated with a polyclonal antibody against the
recombinant cPLA2, and the Amersham ECL system was used for
detection.
Phosphorylation Sites on Cytosolic Phospholipase A2 6994spot 7 region (not shown). In the analysis of some samples of
trypsin-digested cPLA2 from Sf9 cells by HPLC, a small peak of
cpm eluted just prior to peak 4. Two-dimensional phosphopep-
tide mapping analysis of this pre-peak 4 revealed a spot in the
7 region, showing that it is the oxidized phosphopeptide 4 (not
shown). Spot 6, seen in Figs. 9 and 10, requires additional
comment. As seen in these figures, spot 6 is seen with cPLA2
derived from monocytes and Sf9 cells. However, as shown in
Fig. 5, in this map spot 6 (not labeled, between 2 and 4)
represents a small percentage of the total phosphopeptides
from cPLA2 expressed in Sf9 cells. Spot 6 intensity was highly
variable in comparison with the other phosphopeptides and
was seen in only 5 out of 25 independent tryptic digests of
cPLA2 from Sf9 cells. This suggests that spot 6 is either a
partial tryptic fragment or a derivative of one of the other
phosphopeptides. Altogether, these results suggest that the
major phosphorylation sites on cPLA2 from Sf9 cells and mono-
cytes are the same.
DISCUSSION
The Sf9 baculovirus expression system has been used to
study phosphorylation of mammalian proteins using numerous
approaches. Coexpression of protein along with its upstream
activating kinase has resulted in the expression of activated
phosphoprotein (39). Insect cell kinases activated during viral
infection also phosphorylate expressed proteins (26). In addi-
tion, expressed proteins can undergo stimulus-dependent phos-
phorylation in insect cells (40). In this study expression of
cPLA2 in insect cells enabled these cells to release arachidonic
acid, but only after stimulation with either A23187 or okadaic
acid, demonstrating that in this model pathways for the acti-
vation of cPLA2 appear to exist which are similar to those in
mammalian cells. Previously, it was found that cPLA2 is phos-
FIG.9 .Two-dimensional tryptic phosphopeptide maps of
32P-
labeled cPLA2 from human monocytes. Tryptic digests of immuno-
precipitated, gel-purified cPLA2 from unstimulated monocytes (panel
A), from okadaic acid-stimulated monocytes (panel B), from okadaic-
stimulated Sf9 cells (panel C), or from okadaic acid-stimulated mono-
cytes cospotted with okadaic acid-stimulated Sf9 cells (panel D) were
separated by two-dimensional phosphopeptide mapping as described
under “Experimental Procedures.” Phosphopeptides were detected by
autoradiography and are labeled as described under “Results.” The
samples were applied at the spots marked by arrows. Electrophoresis
was run in the horizontal dimension, with the anode on the left, and
chromatography was run in the vertical dimension.
FIG. 10. Two-dimensional tryptic phosphopeptide maps of
32P-
labeled cPLA2 from human monocytes. Tryptic digests of immuno-
precipitated, gel-purified cPLA2 from unstimulated (panel A), from
zymosan-stimulated monocytes (panel B), from okadaic-stimulated Sf9
cells (panel C), or from okadaic-stimulated Sf9 cells cospotted with
zymosan-stimulated monocytes (panel D) were separated by two-di-
mensional phosphopeptide mapping as described under “Experimental
Procedures.” Phosphopeptides were detected by autoradiography and
are labeled as described under “Results.” The samples were applied at
the spots marked by arrows. Electrophoresis was run in the horizontal
dimension, with the anode on the left, and chromatography was run in
the vertical dimension.
Phosphorylation Sites on Cytosolic Phospholipase A2 6995phorylated on Ser-505 during expression in Sf9 cells (27, 37). In
this study we identified three additional serines that are phos-
phorylated on cPLA2 during expression in insect cells. Stimu-
lation of insect cells with okadaic acid resulted in an increase in
phosphorylation of Ser-727 on cPLA2. Phosphorylation of this
site also appeared to be increased in monocytes after stimula-
tion with okadaic acid and opsonized zymosan, suggesting that
this site may have a regulatory role in activation of cPLA2
resulting in arachidonic acid release in mammalian cells.
Although previous studies have suggested that the cPLA2 is
phosphorylated on multiple sites after cell activation, only one
site, Ser-505, which is phosphorylated by MAP kinase, has
been identified (13, 21). Phosphorylation of cPLA2 on Ser-505
also occurs during expression in Sf9 cells possibly by an insect
MAP kinase homolog resulting in activated enzyme and retar-
dation in electrophoretic mobility on SDS-polyacrylamide gels
(24, 27). The recombinant cPLA2 mutant, which has an alanine
replacing Ser-505, does not exhibit this gel shift when ex-
pressed in Sf9 cells (27). However, although cPLA2 is partially
phosphorylated on Ser-505 in unstimulated Sf9 cells, we found
that this is not sufficient to cause these cells to release arachi-
donic acid since stimulation with A23187 or okadaic acid was
required to induce arachidonic acid release. Since neither of
these agonists induced a large increase in phosphorylation at
Ser-505, this suggests that other mechanisms are required for
full activation of cPLA2 leading to arachidonic acid release. It
has now been established that in some systems in addition to
phosphorylation an increase in calcium is required for full
activation (21). For example, stimulation of macrophages with
colony-stimulating factor-1, which does not increase calcium
levels in these cells, can induce phosphorylation of cPLA2 and
activation of MAP kinase without inducing arachidonic acid
release
2 (41). However, agonists that induce an increase in
calcium act synergistically to affect arachidonic acid release
when added with agonists that fully induce a gel shift, such as
colony-stimulating factor-1. These results have led to the hy-
pothesis that an increase in intracellular calcium, to promote
association of the cPLA2 with the membrane, as well as phos-
phorylation of cPLA2 is required for full activation (21, 41).
However, an increase in intracellular calcium does not appear
to be required in some cells as some agonists that can stimulate
arachidonic acid release do not raise intracellular calcium
levels. For example, okadaic acid induces arachidonic acid re-
lease in mouse peritoneal macrophages and activates MAP
kinase but does not raise intracellular calcium levels
2 (23).
Similarly, okadaic acid did not raise intracellular calcium lev-
els in Sf9 cells, unlike the calcium ionophore bromo-A23187
(data not shown). Consequently, the results suggest that
phosphorylation of Ser-727 on cPLA2 in okadaic acid-stimu-
lated Sf9 cells allows association of the cPLA2 with the mem-
brane in the absence of an increase in intracellular calcium
levels. Additional experiments are required to explore this
possibility fully.
Many investigators use the retardation of cPLA2 on SDS-
polyacrylamide gels as an indicator of phosphorylation of
cPLA2 on Ser-505. Recently, MAP kinase (ERK1/ERK2)-inde-
pendent pathways have been implicated in phosphorylation of
the cPLA2 leading to a gel shift (22). The okadaic acid-induced
gel shift (Fig. 3) was independent of the phosphorylation of the
MAP kinase peptide. Okadaic acid slightly increased the level
of phosphorylation of the MAP kinase peptide to levels similar
to those of A23187, but only okadaic acid induced a gel shift,
suggesting that the okadaic acid-induced gel shift was caused
by the phosphorylation of Ser-727.
The kinase that phosphorylates the cPLA2 in insect cells on
Ser-727 has not been identified, but this serine lies within a
consensus sequence for a basotrophic kinase (RXS), such as
protein kinase C or protein kinase A (42, 43). These kinases can
phosphorylate cPLA2, in vitro, but phosphorylation has not
resulted in a consistent increase in enzyme activity (20, 21).
Protein kinase C-dependent pathways have been implicated in
the activation of the cPLA2. PMA, an activator of protein ki-
nase C, can stimulate phosphorylation of cPLA2 in mammalian
cells (13, 19). PMA can also stimulate phosphorylation of the
cPLA2 in insect cells (27). However, since PMA can also acti-
vate MAP kinase in mammalian cells further studies are
needed to determine whether protein kinase C can directly
phosphorylate cPLA2 or whether this kinase produces an indi-
rect effect (23, 44). The results of this study suggest that
Ser-727 is also phosphorylated in okadaic acid- and opsonized
zymosan-stimulated human monocytes, indicating that this
site may be regulated in monocytes during cell activation. The
conservation of Ser-727 (as is seen with Ser-505), even in an
evolutionary distant species such as zebrafish, suggests that
this serine may have an important regulatory role. Ser-454, on
the other hand, which is phosphorylated only to a small extent
in Sf9 cells and monocytes, is not conserved even in the mouse,
whereas Ser-437 is conserved in mouse and chicken (6). In
conclusion, the Sf9 baculovirus expression system is a useful
system for studying cPLA2 phosphorylation and activation and
has led to the identification of multiple novel phosphorylation
sites on cPLA2. Further studies will determine whether these
sites play a functional role in the activation of cPLA2.
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